Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Oncologists who Treat Hematologic Malignancies (US)

Articles with lock require a subscription to GLG News | Request a free trial
March 3, 2008
Teva Camptosar: significance?
Analysis of: Teva Announces Approval Of Generic Camptosar(R) | www.pipelinereview.com
Author: GLG Expert Contributor
Camptosar is being made in Israel I would imagine, and the price differential compared to Pfizer's brand name drug is????
March 3, 2008
"RECORD" would bring record number of approved targted agents for renal cancer
Analysis of: Novartis Late-State Cancer Trial Is Stopped Early After Meeting Goal | online.wsj.com
Author: GLG Expert Contributor
the "Record" trial showed that Novatis' m-Tor inhibitor, everolimus improved progression free survival as compared to placebo in patients with advanced renal cancer who failed several other therapies including Avastin ( Genentech), Nexavar ( Bayer) and/or Sutent ( Pfizer). With The field of targeted...
February 29, 2008
Anesthesia in Colonoscopies: I have an idea for a clinical trial!
Analysis of: Aetna to Delay Reduced Colonoscopy Coverage | online.wsj.com
Author: GLG Expert Contributor
The original plan was to not provide for anesthesia support during the uncomfortable, to say the least, colonoscopys as well as upper endoscopy.
February 28, 2008
Novartis's Everolimus: On it's way to being a competitor for Wyeth's Torisel.
Analysis of: Novartis Late-State Cancer Trial Is Stopped Early After Meeting Goal | online.wsj.com
Author: GLG Expert Contributor
It shares a common mechanism of action with Wyeth's Torisel (mTOR inhibition) and will at least share the market for recurrence after a TK inhibitor fails.
February 27, 2008
Procrit, Aranesp, Epogen: OMG (O my God) now JAMA piles on.
Analysis of: Higher Risks Found for Anemia Drugs | online.wsj.com
Author: GLG Expert Contributor
Meta analysis of multiple papers shows an increased risk of dealth in cancer patients receiving Epo products.
February 26, 2008
CEP-18770 (Cephalon & Cell Therapeutics Europe) an oral proteosome inhibitor: Millenium beware
Analysis of: CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib | bloodjournal.hematologylibrary.org
Author: GLG Expert Contributor
IF this agent works it is ORAL and will certainly be more acceptable to patients than the IV Velcade.
February 26, 2008
Gene Directed Therapy: I told you so!! Roche Holding on the right track!
Analysis of: Study: More Complexity In Tailoring Cancer Drugs | online.wsj.com
Author: GLG Expert Contributor
Roche Holding may well be leading the way to make gene analysis more cost effective and individualize cancer care by targeting the mutations!!
February 26, 2008
Gardasil for boys: Not so tough sell!!!
Analysis of: Vaccinating Boys for Girls’ Sake? | www.nytimes.com
Author: GLG Expert Contributor
Merck's HPV vaccine, Gardasil is expected to be approved for boys to extend "herd immunity" and offer more prevention to girls from cervical cancer. This " altruistic" goal comes with benefits for boys: eradication of 90 % of genital warts cases, and possible long term prevention of anal , penile, and...
February 26, 2008
Accelerated approval for Avastin: Just the beginning
Analysis of: Genentech Clears Hurdle On Cancer Drug Avastin | online.wsj.com
Author: GLG Expert Contributor
As expected, FDA gave accelerated approval for Genetech's Avastin in metastatic breast cancer, thus requiring Genentech to do further studies to show survival benefit and confirm the PFS survival. This decision will "officially" introduces Avastin to breast cancer market, where use has been already...
February 25, 2008
Gardasil: Cervical Cancer Vaccine for Boys?? Can you say disingenuous?
Analysis of: Vaccinating Boys for Girls’ Sake? | www.nytimes.com
Author: GLG Expert Contributor
Merck intends to market this viral vaccine to "protect" women from the risk of cervical carcinoma.

Previous Page : 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Next171 to 180 of 702

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T01:45:24.617